Man Group plc acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 58,380 shares of the biopharmaceutical company's stock, valued at approximately $940,000. Man Group plc owned approximately 0.08% of Xencor at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 3,018 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of Xencor during the second quarter worth $55,000. E Fund Management Co. Ltd. purchased a new stake in shares of Xencor in the second quarter valued at $79,000. iSAM Funds UK Ltd acquired a new position in Xencor in the second quarter valued at $122,000. Finally, Prelude Capital Management LLC purchased a new position in shares of Xencor during the 3rd quarter worth about $139,000.
Wall Street Analyst Weigh In
XNCR has been the subject of several research analyst reports. Truist Financial dropped their price target on shares of Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. Royal Bank Of Canada boosted their price objective on shares of Xencor from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on Xencor from $14.00 to $21.00 and gave the stock a "neutral" rating in a report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Wedbush boosted their price target on Xencor from $26.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $30.71.
View Our Latest Analysis on XNCR
Xencor Stock Down 1.0%
Xencor stock opened at $26.62 on Friday. The firm has a fifty day moving average of $20.83 and a 200-day moving average of $15.22. Xencor, Inc. has a 52-week low of $8.05 and a 52-week high of $30.61. The firm has a market capitalization of $1.98 billion, a P/E ratio of -12.27 and a beta of 0.88.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm had revenue of $51.22 million during the quarter, compared to analysts' expectations of $18.89 million. During the same period in the prior year, the company earned ($0.41) EPS. The firm's revenue was up 17.4% on a year-over-year basis. On average, research analysts expect that Xencor, Inc. will post -3 EPS for the current fiscal year.
Xencor Profile
(
Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
